CXCL10 and head and neck squamous cell carcinoma: Similar to the human HNSCC cell lines, both AZD8931 and trametinib stimulated expression of CXCL10 in B4B8 cells (Fig. 5a), indicating that inhibition of the MAPK signaling pathway is central to the observed transcriptional responses.